Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride

European Urology

Volumn 63, Issue 6, 2013, Pages 1115-1121

  Muller, Roberto L ^a,b   Gerber, Leah ^a,b   Moreira, Daniel M ^c   Andriole Jr , Gerald ^d   Hamilton, Robert J ^e   Fleshner, Neil ^e   Parsons, J Kellogg ^f   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c The Arthur Smith Institute for Urology   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 reductase inhibitors; Dutasteride; Growth and development; Obesity; Prostate; Prostatic hyperplasia; Ultrasonography

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBESITY; ORGAN GROWTH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; SECONDARY ANALYSIS; TESTOSTERONE BLOOD LEVEL; WEIGHT CHANGE;

5-ALPHA REDUCTASE INHIBITORS; AGED; AZASTEROIDS; BIOPSY; BODY MASS INDEX; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; ORGAN SIZE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84876478193     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.02.038     Document Type: Article

References (28)

1. J.T. Wei, E. Calhoun, and S.J. Jacobsen Urologic Diseases in America project: benign prostatic hyperplasia J Urol 179 2008 S75 S80
2. J.K. Parsons Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors Curr Bladder Dysfunct Rep 5 2010 212 218
3. J.K. Parsons, J. Mougey, and L. Lambert Lower urinary tract symptoms increase the risk of falls in older men BJU Int 104 2009 63 68
4. T.V. Johnson, A. Abbasi, and S.S. Ehrlich Major depression drives severity of American Urological Association Symptom Index Urology 76 2010 1317 1320
5. H. Marklund, A. Spangberg, and U. Edell-Gustafsson Sleep and health-related quality of life in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the general population and patients with inguinal hernia Scand J Urol Nephrol 44 2010 304 314
6. J.K. Parsons, A.V. Sarma, K. McVary, and J.T. Wei Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions J Urol 189 2013 S102 S106
7. J.K. Parsons, H.B. Carter, and A.W. Partin Metabolic factors associated with benign prostatic hyperplasia J Clin Endocrinol Metab 91 2006 2562 2568
8. L.P. Xie, Y. Bai, and X.Z. Zhang Obesity and benign prostatic enlargement: a large observational study in China Urology 69 2007 680 684
9. A.R. Kristal, K.B. Arnold, and J.M. Schenk Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial J Urol 177 2007 1395 1400 quiz 1591
10. S. Lee, H.G. Min, and S.H. Choi Central obesity as a risk factor for prostatic hyperplasia Obesity (Silver Spring) 14 2006 172 179
11. L.P. Wallner, H. Morgenstern, and M.E. McGree The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection Cancer Epidemiol Biomarkers Prev 20 2011 501 508
12. C. Ozden, O.L. Ozdal, G. Urgancioglu, H. Koyuncu, S. Gokkaya, and A. Memis The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia Eur Urol 51 2007 199 206 discussion 204-6
13. C.G. Roehrborn, P. Siami, and J. Barkin The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol 57 2010 123 131
14. G. Andriole, D. Bostwick, and O. Brawley Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial J Urol 172 2004 1314 1317
15. C. Wu, D.M. Moreira, L. Gerber, R.S. Rittmaster, G.L. Andriole, and S.J. Freedland Diabetes and prostate cancer risk in the REDUCE trial Prostate Cancer Prostatic Dis 14 2011 326 331
16. F. Lotti, G. Corona, and G.M. Colpi Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility J Endocrinol Invest 34 2011 e336 e342
17. E. Giovannucci, E.B. Rimm, and C.G. Chute Obesity and benign prostatic hyperplasia Am J Epidemiol 140 1994 989 1002
18. S. Wang, Q. Mao, and Y. Lin Body mass index and risk of BPH: a meta-analysis Prostate Cancer Prostatic Dis 15 2012 265 272
19. E.A. Platz, C.E. Joshu, A.M. Mondul, S.B. Peskoe, W.C. Willett, and E. Giovannucci Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men J Urol 188 2012 496 501
20. K.M. Flegal, M.D. Carroll, B.K. Kit, and C.L. Ogden Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 JAMA 307 2012 491 497
21. S.P. Stroup, K. Palazzi-Churas, R.P. Kopp, and J.K. Parsons Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008 BJU Int 109 2012 84 87
22. G.M. Keating Dutasteride/tamsulosin: in benign prostatic hyperplasia Drugs Aging 29 2012 405 419
23. R.V. Clark, D.J. Hermann, G.R. Cunningham, T.H. Wilson, B.B. Morrill, and S. Hobbs Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor J Clin Endocrinol Metab 89 2004 2179 2184
24. J.K. Parsons, J.M. Schenk, and K.B. Arnold Finasteride reduces the risk of incident clinical benign prostatic hyperplasia Eur Urol 62 2012 234 241
25. J.K. Parsons, K. Palazzi-Churas, J. Bergstrom, and E. Barrett-Connor Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study J Urol 184 2010 1040 1044
26. S.J. Freedland, W.B. Isaacs, and E.A. Platz Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study J Clin Oncol 23 2005 7546 7554
27. A.W. Partin, J.E. Oesterling, J.I. Epstein, R. Horton, and P.C. Walsh Influence of age and endocrine factors on the volume of benign prostatic hyperplasia J Urol 145 1991 405 409
28. J.M. Schenk, A.R. Kristal, and M.L. Neuhouser Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial Prostate 69 2009 1303 1311